Bristol-Myers Squibb BMY
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 37th percentile, 5-year average 9.8x
#1030 of 2972 stocks by PE (1 = cheapest)
Above its usual level · 61st percentile, 5-year average 5.1x
#4447 of 5311 stocks by PB (1 = cheapest)
Around its usual level · 53rd percentile, 5-year average 2.6x
#2853 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 5.46 | – | 5.11 | 61% (pricier than usual) | #4447 of 5311 (1 = cheapest) |
| PE | 13.85 | 11.82 | 9.78 | 37% (cheaper than usual) | #1030 of 2972 (1 = cheapest) |
| PS | 2.55 | 2.62 | 2.62 | 53% (pricier than usual) | #2853 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on BMY.
Sign in to join the discussion.